Primepoint | $10,000,000 | (Apr 14, 2026)
Qoro | $750,000 | (Apr 14, 2026)
Remission Medical | Undisclosed Amount | (Apr 14, 2026)
Cambrian BioPharma
United States
- New York, New York
- 26/10/2021
- Series C
- $100,000,000
Cambrian BioPharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.
As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.
- Industry Biotechnology Research
- Website https://www.cambrianbio.com/
- LinkedIn https://www.linkedin.com/company/cambrianbio/about/
Related People
James Peyer, PhDFounder
United States -
New York City Metropolitan Area
As Founder and CEO of Cambrian Bio, a Distributed Drug Development Company (or a "DisCo" as we like to call it), I’m focused on developing therapeutics targeting the biological drivers of aging. Cambrian builds, directs, operates, and finances a pipeline of therapeutics. I founded the company to translate laboratory breakthroughs in the extension of healthy lifespan into the clinic, because the world is entering a revolution in medical research that will change our relationship with medicines from REactive to PROactive. Learn more: www.cambrianbio.com
Before Cambrian, I started Apollo Ventures, the first company builder in Longevity Therapeutics, where I was founder, investor, and CEO of multiple companies. I did my PhD with a focus on blood stem cell biology as a National Science Foundation Fellow at UT Southwestern.
Pixel Photonics | $5,880,875 | (Apr 14, 2026)
Critical Loop | $26,000,000 | (Apr 14, 2026)
AIRMO | $5,880,175 | (Apr 14, 2026)
Blocks | $6,000,000 | (Apr 14, 2026)
Slate Auto | $650,000,000 | (Apr 14, 2026)
Citra Space Corporation | $15,000,000 | (Apr 14, 2026)
Flashpass | $4,250,000 | (Apr 14, 2026)
Sigma Automate | $2,750,000 | (Apr 10, 2026)
Felix(1) | $1,700,000 | (Apr 10, 2026)